The ACR Convergence program includes content related to the clinical practice and teaching of rheumatology. Abstracts covering basic and translational science that contributes to the understanding of musculoskeletal and rheumatic disease pathogenesis, therapeutic mechanisms and efficacy, and studies investigating healthcare delivery to patients are eligible for submission.

The fee for submitting each abstract is $100. The ACR accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds. All fees are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.

SUBMISSION DEADLINE: Thursday, June 18, 2024, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.

The ARP program reflects the needs and interests of healthcare professionals with an interest in rheumatology-related issues by offering a forum to address significant issues with a multidisciplinary audience. Abstracts will be peer reviewed by a subsection of the ARP Annual Meeting Program Subcommittee according to subject categories. ARP abstract sessions will not necessarily be scheduled by individual category.

A $50 processing fee accompanies each ARP abstract submission. The ARP accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds and are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.

SUBMISSION DEADLINE: Thursday, June 18, 2024, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.

Persons Eligible to Submit

• Members and non-members of the ACR and ARP are eligible to submit an abstract.
• Employees or owners of ineligible companies may be the presenting author of an abstract. Abstract sessions do not have CME credit.

Abstracts Eligible for Submission

• Abstracts that have been previously accepted and/or presented at other medical meetings and published in conference proceedings (“encore” abstracts) are eligible for submission. These abstracts will go through the same peer review process as any other abstracts.
• Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
• Abstracts reporting results of a clinical trial will be required to identify the trial phase.
• Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

Abstracts Not Eligible for Submission

• Abstracts should not report results that have been previously presented at an ACR/ARP Annual Meeting.
• Abstracts that report work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the submission deadline of noon ET on Tuesday, June 18, 2024, are ineligible for consideration.
• Multiple abstracts may not be submitted for one study unless substantially different research questions are being addressed in each abstract.
• Abstracts submitted for the ARP program may not be concurrently submitted to the ACR program.
• Case reports are not considered appropriate and will not be reviewed. We encourage those with interesting cases or images to consider submission to the Thieves Market, Image Competition or Global Summit. See separate submission processes.